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                                                  Abstract 
Alsabri, Sami Gammaleddin F. M.S. Department of Pharmacology and Toxicology, 
Wright State University, 2017. Usage of Extracellular Microvesicles as Novel and 
Promising Therapeutic Tool in Wound Healing. 
Introduction Extracellular Microvesicles (EMVs) can carry genetic messages and 
biologically active proteins throughout tissues and the body. Because of their transport 
capabilities, EMVs play an important role both diseased and healthy conditions. For 
example, EMVs play an important regenerative role in many damaged tissues. In the 
current studies, we examine the role of EMVs in epithelial wound healing. The potential 
use of EMVs as drug delivery vehicles has gained considerable scientific interest because 
they can be delivered in circulation, can be targeted to specific areas/cells, and can pass 
natural barriers. In the current work, we investigate the potential of EMVs or EMVs loaded 
with growth factors as a tool to enhance cell migration in order to accelerate epithelial 
wound healing.  
Material and Methods Spontaneously immortalized skin keratinocyte and macrophage 
cells were stressed for 48 h by serum free media to enhance the release of the EMVs from 
keratinocytes (KMVs) and macrophages (MMV). The EMVs from both cell lines were 
isolated and collected using a centrifugation process. Specifically, the collected serum free 
media were centrifuged at 4 °C (500 × g for 10 minutes followed by 2,000 × g for 20 
minute). The supernatant was then centrifuged at 24,000 × g for 2 hours to isolate EMVs. 
EMVs were “loaded” with growth factors by incubating them for 1.5 h at room temperature 
iv 
 
with PDGF, TGF-β, VEGF, and FGF (25ng/ml per each). These “loaded” EMVs were then 
ultra-centrifuged at 176,000 x g for 3 h to re-pellet the loaded microveiscles derived from 
keratinocytes KMVs (LKMVs) or macrophages MMVs (LMMVs).  
In order to evaluate the role of microvesicles on cutaneous wound healing, we chose 
the in vitro wound scratch assay to evaluate the cell migration rate and the wound healing 
percent after adding of KMVs, LKMVs, MMVs, and LMMVs separately to Epidermal 
keratinocytes culture. Epidermal keratinocytes were plated into 6 well plates, and wound 
scratch was made using 10 µl pipette tip. The model was visualized by 10 x magnification 
power of EVOS XL Core Cell Imaging System and analyzed using Mat lab software to 
measure wound area. 
MTT assay was used to evaluate the proliferative effect of KMVs, LKMVs, MMVs, 
and LMMVs on Epidermal keratinocytes. The loading was confirmed by using BioPlex 
Pro cytokine assays. 
Results after 72 h, the wound area in the EMVs (KMVs & MMVs) and LEMVs (LKMVs 
& LMMVs) treated groups showed a significant decrease in wound area and a remarkable 
ability to repair the wound area as compared with the control group (P < 0.0001). The 
percent of wound healing was almost three times more in KMVs and MMVs treated groups 
(57.85 % ±3.13, 69.84 % ± 4.87, respectively), and four times in LKMVs and LMMVs 
treated groups (80.10% ±3.50, 90.87% ±2.00, respectively) when compared to the control 
groups (21.74 % ± 2.389) (P < 0.0001). Furthermore, the migration rate in the presence of 
KMVs and MMVs (0.008810 ± 0. 0006856, 0.01085 ±0.0007964 mm2/h, respectively) 
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and LKMVs and LMMVs (0.01470 ± 0.0009428, 0.01767 ±0.001163 mm2/h, 
respectively) were enhanced when compared to the control group (0. 003820 ± 0. 0003760 
mm2/h). 
Conclusion EMVs and Loaded EMVs have a potential regenerative effect in wound 
healing, which promotes and enhances cell migration and proliferation, resulting in 
accelerated wound closure. Based on these finding, we suggest that EMVs are a novel and 
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Introduction 
Skin is the largest organ in the body. It works as a protective layer against toxins 
and microorganisms, and provides chemical protection against invasion by toxins and 
microorganisms. Skin also plays an important role in thermoregulation and prevention of 
dehydration. (Choi, Uyama, Lee, & Sung, 2015)  
Wounds  
A wound can be defined as a breakdown in the protective function of the skin. 
Wounds can also be defined as disruption in the epithelial lining of the skin or mucosa due 
to either physical or thermal injury (Dhivya, Padma, & Santhini, 2015). Generally, wounds 
are classified as acute or chronic. Clinically, acute wounds are defined as wounds with high 
tendency to heal in a short period of time (< 3 months), while chronic wounds have little 
or no tendency to healing (≥ 3 moths). 
Chronic wounds   
Chronic wounds have increased in prevalence over the last few decades. Chronic 
wounds affect 1-2 % of the population in the United States, which results in an increase in 
the health care burden. These injuries cost the US health care system around 50 billion 
dollars yearly, with an average cost of $3.349 to 9.358 per wound. Furthermore, current 
treatments for chronic wounds do not guarantee wound closure, and recurrence is common.
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Therefore, the development of effective chronic wound treatments is an important issue 
that could increase the effectiveness of health care resources worldwide (Gainza et al., 
2015). Scientists have not only focused on developing new modalities of treatment, but 
also improving the efficacy of existing treatments. Here we focus upon the use of growth 
factors (GFs) for wound healing (Gainza et al., 2015).  
Wound healing 
Epithelial wound healing occurs in stages. Understanding the stages of wound healing 
at the molecular level is essential to developing treatment. This may helps in not only reduce 
morbidity and mortality related to abnormal or prolonged wound healing but also in finding 
and introducing new approaches and therapeutics tools. Cutaneous wound healing is a 
multistep and highly sophisticated systematic process. It includes many cell types, soluble 
mediators, and extracellular matrices (Robson et al., 2001) a long with a highly dynamic 
coordination between complex cascades of cellular events. These events begin when 
wounding occurs in a process meant to restore and/or replace the damaged and/or missing 
tissues (Rieger et al., 2014). Furthermore, wound healing is characterized by a series of 
overlapping time dependent phases. These include the hemostatic phase (time of injury up 
to several hours after injury), inflammatory phase (1 to 3 days), proliferative phase (4 to 
21 days), and remodeling phase (21 days up to 18 months) (Landén et al., 2016). Disruption 
in any of these phases results in healing impairment and the potential for chronic wounds 
(Landén et al., 2016, Shi et al., 2013). Unfortunately, current therapeutic tools for chronic 
wounds still do not achieve the complete healing, and do not prevent wound recurrence.  
Thus, the development of a novel, effective treatment is needed. (Dhivya et al., 2015; 
Rosique, Rosique, & Farina Junior, 2015).
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Growth factors in wound healing  
The wound healing process is affected by growth factors. Therefore, growth factors 
have been extensively studied over the past decades. Growth factors contribute and regulate 
the cell migration and proliferation in order to accomplish healing as a response to tissue injury 
(Molloy, Wang, & Murrell, 2003; Rosique et al., 2015). Several growth factors have been 
proven to have a role in inflammation (explained below) where they have been shown to 
improve wound healing (Efron and Moldawer 2004). Furthermore, down regulation of growth 
factor proteins has been reported in chronic wounds and has been hypothesized to be one 
possible cause of wound chronicity (Barrientos et al., 2008). 
Platelet derived growth factor (PDGF) 
PDGF is produced by secreted by platelets, macrophages, vascular endothelium, 
fibroblasts, and keratinocytes. PDGF induces cell proliferation, angiogenesis and 
chemotaxis. In fact, PDGF has a significant role in each phase of healing process (Efron 
and Moldawer 2004).  
During the inflammatory phase, PDGF serves as a strong stimulant for mitogenicity 
and chemotaxis of neutrophils, macrophages, fibroblasts, and smooth muscle cell 
migration to the wound site (Barrientos et al., 2008). PDGF also enhances the release of 
several growth factors. For example, TGF-β can be produced by macrophages as a result 
of direct induction of PDGF. Later, TGF-β along with PDGF enhance macrophage 
mediated tissue cleanup, and formation of granulation tissue in the proliferation phase.  
Regarding to angiogenesis, in vitro PDGF, synergistically with hypoxia, shows 
ability to induce formation of new blood vessels by enhancing of VEGF expression, and it 
is particularly essential in in blood vessel maturation (Hu & Huang, 2015). In vitro PDGF 
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has been shown to induce reepithelialization through upregulation of IGF-1 and 
thrombospondin-1 synthesis, which increase keratinocyte motility, delays proteolytic 
degradation, and indorses a proliferative response in keratinocytes in the wound healing 
(Barrientos et al., 2008). Similarly, PDGF can increase fibroblast proliferation and regulate 
collagen production, which are required during the proliferative phase of wound healing 
(Hu & Huang, 2015).  
In the remolding phase, PDGF can increase the degradation of collagen by 
regulating matrix metalloproteinases (Jinnin et al., 2004). In all stages of wound healing, 
PDGF plays a vital role by stimulating the release of the pro-healing cytokines at site of 
injury.  
Transforming growth factor beta (TGF-β)  
TGF-β is a family of pluripotent cytokines. TGF-β has three isoforms: TGF-β 1, 2, 
and 3 with a dominant role of TGF-β 1 in cutaneous wound healing. It can be released by 
keratinocytes, platelets, monocytes, macrophages, and fibroblasts (Rolfe et al., 2007 and 
Barrientos et al., 2008) 
In homeostasis normal conditions, TGF-β has been found to regulate the 
keratinocyte cell cycle and inhibit proliferation. Therefore, TGF-β plays a role in 
maintaining skin homeostasis. TGF-β is a crucial key factor in the wound healing process 
(Siegel & Massagué 2003, Ramirez et al., 2014). It plays a significant regulatory role at all 
the tissue regeneration stages, including, the inflammation, re-epithelialization, 
angiogenesis, and granulation tissue formation (Efron and Moldawer 2004, Guasch et al., 
2007, Barrientos et al., 2008).  
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In wounds, TGF-β has been found to have pleiotropic effects, and regulates the 
functions of keratinocytes, fibroblasts, endothelial cells, monocytes, and other cell types 
that are required in the regenerative process (Ramirez et al., 2014).  
In nonhealing wounds, booth in vitro and in vivo data show that TGF-β can suppress 
the growth and maintenance of epidermal homeostasis (Guasch et al., 2007). Multiple 
studies have also demonstrated that TGF-β expression is suppressed in the epidermis of 
chronic wounds (Ramirez et al., 2014). Several mouse models have shown that exogenous 
application of TGF-β enhanced wound healing by activating TGF-β signaling (Barrientos 
et al., 2008). Clinically, in chronic ulcers, suppression of TGF-β signaling may contribute 
to the loss of tissue homeostasis because of the hyperproliferation and the inability of 
keratinocytes to migrate, epithelialize, and close the wound. 
During the inflammatory stage, TGF-β plays a pro-inflammatory role as a 
chemotactic agent for monocytes infiltration to the wound site. It can also differentiate 
macrophages that clean up the wound site, and play an anti-inflammatory role. During the 
proliferative stage. In proliferative stage, TGF-β is involved in angiogenesis and initiates 
granulation tissue formation. This occurs by up-regulating the expression of fibronectin, 
collagen types I and III, vascular endothelial growth factor (VEGF), and protease inhibitors. 
TGF-β also down regulates MMP expression, which further promotes the accumulation of 
collagen fibers (Barrientos et al., 2008). Furthermore, TGF-β induces the wound 
contraction by inducing smooth muscle alpha actin expression in fibroblasts and myo-




Vascular endothelial growth factor (VEGF) 
VEGF, also called vascular permeability factor, is a homodimeric glycoprotein, and 
one of the most important vascular regulators of vasculogenesis and angiogenesis during 
the injury healing process (Hoeben et al., 2004). VEGF is secreted from platelets, 
keratinocytes, macrophages, neutrophils, endothelial cells, smooth muscle cells, and 
fibroblasts (Barrientos et al., 2008). VEGF is involved in wound repair by triggering 
angiogenesis, chemotaxis, and inducing vascular permeability (Bao et al., 2009) during the 
during the wound healing process (Cooper et al., 1999).  
VEGF has distinctive effects on many components of the wound healing cascade, 
comprising angiogenesis, epithelialization, and collagen deposition (Tomic-Canic et al., 
2007). Since angiogenesis has a vital role in the wound reconstructing process, VEGF 
(alone or in combination therapy) may be utilized in the future for patients with non-healing 
chronic wounds. According to in vitro studies, VEGF initiates the early events in 
angiogenesis, chiefly migration and proliferation of endothelial cell (Lamalice et al., 2007).  
Fibroblast Growth Factor (FGF) 
Since its discovery as a family of growth factors, FGFs are known to play a role in 
a variety of biological processes including differentiation, migration, proliferation, 
angiogenesis, and wound healing (Nakamichi et al., 2016). FGFs are released from many 
cells including macrophages, mast cells, keratinocytes, fibroblasts, smooth muscle cells in 
the wound environment. During the inflammatory stage, FGF has a role in recruiting 
several inflammatory cells, such as neutrophils and monocytes to the wound site. In 
addition, FGF induces the expression of several chemokines, and encourages mitogenesis 
of endothelial cells (Nakamichi et al., 2016). As a growth factor, FGF plays a critical role 
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in re-epithelialization, formation of granulation tissue and tissue remodeling. Several in 
vitro studies have revealed that FGF controls extracellular matrix deposition, enhances 
both keratinocyte migration and proliferation augments fibroblast migration, activates the 
release of collagenase, and additionally improves endothelial cell growth and migration. 
(Teven et al., 2014). In vivo studies, FGF administration can improve healing in diabetic, 
ischemic, and bacterial contaminated wounds. In clinical trials, FGF administration has 
proven to be efficacious for earlier wound closure in pressure ulcers, burns, chronic dermal 
ulcers, and operative wounds (Barrientos et al., 2008).  
Extracellular microvesicles (EMVs) 
EMVs are lipid membrane-bound vesicles, which are shed by almost all cell types 
into the extracellular environment. The release of EMVs is one of the ways cells 
communicate in both healthy and pathological conditions (Camussi et al., 2010). These 
EMVs can deliver many bioactive molecules such as cytokines and growth factors (Fais et 
al., 2016). Likewise, they can deliver a biological message to recipient cells in normal 
physiological and diseased conditions (Fais et al., 2016, Waldenström et al., 2012). 
Moreover, EMVs have been found to have a regenerative effect in several tissues from 
several origins. Recently, phase IV double-blinded clinical trial conducted by Simman et 
al. showed that there is a correlation between EMVs and the rate of wound healing 
(Simman et al., 2016). The decline of growth factors in chronic wounds, the need for a 
more effective treatment for wounds, and the evidence for the potential role of EMVs in 
tissue repair, have prompted us to investigate, the potential effect of growth factors loaded 
EMVs may have to enhance and accelerate wound healing. 
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EVs as drug delivery systems 
Today, EMVs are extensity under scientific investigation as a potential drug 
delivery system because of their capabilities to cross the biological barriers and targeting 
specific cells. Furthermore, loading of the therapeutic agents into EMVs increased the 
circulation time, preserve the therapeutic activity, and improve the drug solubility (Somiya 
et al., 2017). In order to load EMVs, different methods have been invented and validated. 
These methods include: incubation at room temperature (RT) with or without saponin 
permeabilization, freeze-thaw cycles, and sonication. Loading of EMVs has been exploited 
in several investigations, anticancer such as Paclitaxel (Saari et al., 2015), antioxidant such 
as catalase enzyme to treat Parkinson disease (Haney et al., 2015) was successfully loaded, 
and loaded EMVs showed a strong effect compared with free drug in in vivo and in vitro 
model (Ha et al., 2016). In this work, we chose incubation at room temperature to load 
growth factors into EMVs because the other methods mentioned above may affect the 
nature and activity of the growth factor proteins.   
Hypothesis 
“The usage of EMVs as a novel and promising therapeutic tool in the wound 
healing area will induce and enhance tissue repair process.” 
Specific Aims 
1. Evaluate the effect of EMVs on the wound healing process (cell migration and 
proliferation). 
2. Load the EMVs with growth factors (TGF-β, PDGF, FGF, and VEGF). 
3. Assess the outcome of the loaded EMVs on wound healing process (cell migration and 
proliferation) with compare to unloaded EMVs. 
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Materials and methods 
Reagents 
Optimized Dulbecco's Modified Eagle Medium (DMEM) was purchased from 
AddexBio.  Corning™ Regular Fetal Bovine Serum (FBS). HyClone™ Penicillin-
Streptomycin, HyClone™ Dulbecco's Phosphate Buffered Saline (DPBS), Gibco™ 
Trypsin-EDTA (0.25%), and Thermo Scientific™ Biolite 6 Well were purchased from 
Fisher Scientific. 
Cell Culture 
The spontaneously immortalized skin keratinocyte cell line (HaCaT) from 
AddexBio was cultured in optimized DMEM (contains 2 mM L-glutamine, 2 mM sodium 
pyruvate, 4500 mg/L glucose, and 1500 mg/L sodium bicarbonate) supplemented with 10 
% FBS, 1 % penicillin-streptomycin and incubated at 37 oC with 5 % CO2 in a humidified 
atmosphere.  
EMVs release and isolation 
HaCaT and Macrophage cells were cultured respectively in serum free DMEM and 
Ham's F-12 media for 48 h to enhance the release of keratinocytes derived microvesicles 
(KMVs.) and macrophages derived microvesicles (MMVs) (Silva et al., 2015). After 48 h, 
the medium was collected and centrifuged at 500 x g for 10 mins followed by 2000 x g for 
20 minutes to remove cell debris using Eppendorf ® centrifuge 5810 R. Then the 
supernatant was Centrifuged at 24,000 x g for 2 hours using a S0RVALL® Discovery M120 
SE ultracentrifuge to isolate the KMVs and MMVs. Isolated KMVs and MMVs were 




 The EMVs were incubated for 1.5 hours at room temperature with PDGF, VEGF, 
FGF, and TGF–beta (25 ng/ml of each). They were then ultra-centrifuged for 3 hours at 
176 K G to re-pellet the EMVs., followed by 2-time wash with PBS to remove any extra 
vesicles growth factors remained (Saari et al., 2015).    
Nanoparticle tracking analysis (NTA) 
NanoSight (NS300) with a 405-nm laser instrument was used to detect the presence 
of EMVs particles (Figure 1). 10 microliters of EMVs sample was diluted 70 times in 690 
µl Filtered PBS and three 30 second videos were recorded using camera level 13 at 25 
frames per second. The data were analyzed using NTA software 3.0 software (Malvern 
Instruments) which was optimized to first identify and then track each particle on a frame-
by-frame basis. The detection threshold optimized for each sample and screen gain at 5 to 
track as many particles as possible with minimal background (JinjuWang et al., 2016, Saari 









Figure 1: Average Concentration / Size of Extracellular microvesicles. 
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Wound-scratch assay model 
In this model, Epidermal keratinocytes were seeded into 6 well plates (150,000 
cell/well). After wells Confluency, cells were starved in DMEM media supplemented with 
low FBS concentration (0.5 %) overnight. On the next day, wound scratches were made 
using a 10 µl pipette tip, and single dose of EMVs in DMEM/0.5 % FBS was added (2ml/ 
well). The wells were visualized by 10 x magnification power of EVOS XL Core Cell 
Imaging System with CMOS camera sensor at zero time and after 72 hours. The images 
were analyzed using Mat lab software to measure the wound area in pixels. To convert area 
in pixels to microns, we used the following equation (Stpierre, & Shetty 2008):  
(µm2/pixel) = Physical length of a pixel on camera sensor (12) / total magnification power 
(10) = (1.2 µm2 = 1 pixel). 
Cell Proliferation Assay (MTT Assay) 
Colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay kit (5 mg/ml in RPMI-1640 without phenol red) from Sigma was used to 
assess the metabolic (reduction) activity of NAD(P)H-dependent cellular oxidoreductase 
enzymes on converting yellow MTT dye to purple formazan, which reflect the number of 
viable cells. MTT stock solution (5 mg/cc) is appended to each culture being assayed to 
equal one-tenth the original culture volume and incubated for 4 hours. At the final stage of 
the incubation period the medium was removed and the converted dye was solubilized with 
acidic isopropanol (0.1 N HCl in absolute isopropanol). Absorbance of converted dye was 




Growth Factors Analysis 
 In order to analyze the growth factors levels inside the microvesicles, we used the 
Bio-PLex system. 100μl 1XPBS was added to each sample, and protein concentration was 
determined using the Bradford assay. A (Bio-Rad) BioPlex 96 well plate was set up with 
50 µl of the sample and duplicated for cytokine analysis using Bio-Plex (Bio-Rad) Human 
Cytokine 27-Plex Group 1 assay kits. To each well. Buffer and magnetic beads were added 
and washed on the magnetic plate washer. The plate was run on the Bio-Plex 200 system 
at a low PMT setting followed by high PMT according to Bio-Rad instructions. 
  
Figure 2. shows the level of FGF-b inside the loaded and 
un-loaded EMVs from keratinocytes and macrophages.  
“*” means that the level of FGF-b is more than standard 
range.  
Figure 3. shows the level of PDGF-bb inside the loaded and 
un-loaded EMVs from keratinocytes and macrophages.  
“*” means that the level of PDGF-bb is more than standard 
range. “#” means that the level of PDGF-bb is less than the 



































































Figure 4. shows the level of VEGF inside the loaded and un-loaded EMVs from 
keratinocytes and macrophages. “#” means that the level of VEGF is less than 
standard range.  
 
Statistical analysis 
 The data analysis was conducted by using the Prism 6 software. The Experiment 
was performed and repeated three times with independent HaCaT cultures. Wound area, 
wound healing, and migration rate data are represented as mean ± SEM, analyzed using t-
test with unequal variances and one-way ANOVA test. The results were considered 
significant at P ≤ 0.05. 
Results  
Several studies have discussed the potential role of microvesicles in tissue repair 
due to their role in intercellular communication (Saari et al., 2015). Therefore, in this study, 
the wound - scratch assay was performed to examine whether treatment with EMVs 
accelerate the wound closure of a wounded monolayer of differentiated and living skin 
keratinocytes (HaCaT). The wounded areas in both groups were created by scratching the 
plates with monolayer cells. The initial wounded area in both groups was similar with no 
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Figure 5: Shows the Initial Wound Area in the Control, KMVs treated, LKMVs treated, MMVs treated, 
and LMMVs Groups at zero time with no significant difference in wound area between the Groups (P > 
0.05). 
Table 1: Average of initial wound area at zero   
Dependent variable: wound area 
Groups Mean Std. 
Deviation 
S.E.M ± N 
Control  1.320 0.4421 0.07368 36  
MVs  1.142 0.4219 0.07703 30 
LKMVs 1.384 0.4861 0.1036 22 
MMVs 1.154 0.2767 0.06187 20 
LMMVs 1.372 0.3143 0.08400 14 
ANOVA: single factor: F= 1.908, df (4, 117), (P > 0.05).  
 
In the control group, the cells showed little ability to repair the wound area, whereas 
in EMVs and LEMVs treated groups, the cells were shown to be able to repair the wound 
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Figure 6. Wound scratch assay shows EMVs and LEMVs from macrophages and keratinocytes accelerate 
wound closure. Representative inverted microscope images depicting EMVs and LEMVs potential impact 
on cell migration in differentiated, live HaCaT cells. In the control group (A, B), cells cultivated in 0.5 % 
FBS/DMEM from the time of wounding: 0 h (A) and 72 h (B) after wounding. In EMVs and LEMVs treated 
groups (C - J), cells cultivated in 0.5 % FBS/DMEM with single dose of EMVs or LEMVs from the time of 
wounding: dose of EMVs and LEMVs from keratinocytes 0 h (C, E), and 72 h after wounding (D, F). dose 
of EMVs and LEMVs from macrophages 0 h (G, I), and 72 h after wounding (H, J). (K- O) show the new 
cells file the wound area of (B, D, F, H, J) after 72 h (n = 3). 
 Wound area was measured after 72 hours. There was a significant decrease in 
wound area in LEMVs (LKMVs & LMMVs) and EMVs (KMVs & MMVs) treated groups 
in comparison with the wounded area in the control group (P < 0.0001), whereas, LEMVs 
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Figure 7: Shows Wounded Area Post 72 Hours in the Control, KMVs treated, LKMVs treated, MMVs 
treated, and LMMVs treated groups. There is a significant decrease in wound area in the Treatment Groups 
as compared with the Control Group (P < 0.0001), and substantial drop in wound area in LKMVs and 
LMMVs as compared with control group (P < 0.0001), and KMVs and MMVs (P < 0.01).   
Table 2: Average of wound area post 72 h   
Dependent variable: wound area 
Groups Mean Std. 
Deviation 
S.E.M ± N 
Control 1.045 0.4129 0.06882 36 
KMVs 0.5054 0.3232 0.05900 30 
LKMVs 0.3256 0.2958 0.06307 22 
MMVs 0.3938 0.3013 0.06736 20 
LMMVs 0.1369 0.09597 0.02565 14 
ANOVA: single factor: F= 29.55, DF (4, 117), (P <0.0001).  
 
In addition, the average percentage of wound healing was around three times higher 
in the presence of EMVs. (57.85 % ±3.13, 69.84 % ± 4.87) when compared with the control 
group (21.74 % ± 6.12) (P < 0.0001). Wound healing was four time higher in presence of 
LEMVs (80.10 % ± 3.50, 90.87 % ± 2.00) as compared with the control, and around one 
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time more (P < 0.01) as compared with EMVs group (57.85 % ±3.13, 69.84 % ± 4.87) 
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Figure 8: Shows the Percent of Wound Healing in Control, KMVs treated, LKMVs 
treated, MMVs treated, and LMMVs treated Groups with a significant increase in the 
wound healing percentage in KMVs and MMVs Groups as compared with the Control 
Group (P < 0.0001), and substantial increase wound healing percentage in LKMVs and 
LMMVs groups as compared with control, KMVs, and MMVs (P < 0.0001).   
Table 3: Average of wound healing percentage   
Dependent variable: wound healing 
Groups Mean Std. Deviation S.E.M ± N 
Control 21.74 14.33 2.389 36 
KMVs 57.85 16.86 3.130 30 
LKMVs 80.10 16.45 3.506 22 
MMVs 69.84 21.25 4.876 20 
LMMVs 90.87 7.070 2.041 14 
ANOVA: single factor: F= 70.22, DF (4, 117), (P <0.0001).  
 
In addition, we noticed a clear change in cell morphology in EMVs and LEMVs 
treated groups when compared with Control group. The cells residing at the edge of the 
wounds became more stretched and elongated (Figure 6 K-O). Cell migration is defined 
as cell movement into the wound area. For this reason, we calculated the cell migration 
19 
rate for all groups, and it was significantly higher in EMVs and LEMVs treated group (P 
< 0.0001) when compared with the control group, and it was higher in LMVs groups as 
compared with EMVs groups (P < 0.0001) (Figure 9).  
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Figure 9: Shows the Cells Migration Rate in the Control, KMVs, LKMVs, MMVs, and LMMVs Groups. 
The cells migration rate in KMVs and MMVs Group were significantly higher as compared with the Control 
Group (P < 0.0001), LKMVs and LMMVs groups were substantially remarkable as compared with KMVs, 
MMVs, and Control (P < 0.0001),    
Table 4: Average of migration rate (mm2/h) 
Dependent variable: migration rate 
Groups Mean Std. 
Deviation 
S.E.M ± N 
Control 0.003820 0.002256 0.0003760 36 
KMVs 0.008810 0.003692 0.0006856 30 
LKMVs 0.01470 0.004422 0.0009428 22 
MMVs 0.01085 0.003472 0.0007964 20 
LMMVs 0.01767 0.004030 0.001163 14 
ANOVA: single factor: F= 53.86, DF (4, 117), (P <0.0001).   
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Furthermore, we calculated the area covered by the migrated cells in the both 
groups based on their migration rate, this covered area was approximately threefold higher 
in EMVs treated group, and four time in LEMVs treated groups (P < 0.0001) as compared 
to the control group at 24, 48, and 72 hours (P < 0.0001). The migration rate in LEMVs 
was one time more than EMVs groups (P < 0.01) (Figure 10). 
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Figure 10: Shows the wound area covered by migrated cells was calculated at 24, 48, and 72 hours in the 
Control, KMVs, LKMVs, MMVs, and LMMVs, this covered area was approximately threefold higher in 
EMVs treated groups as compared with the control group at three time points (P < 0.0001). LEMVs groups 
was almost four times more as compared with the control group (P < 0.0001), and one time more when 
compared with the EMVs groups (P < 0.01).   
Table 5: Average of wound covered area  
Dependent variable: wound covered area 
Group Time (h) Mean Std.  
Deviation 




24 0.09169 0.05414 0.009023  
36 48 0.1834 0.1083 0.01805 
72 0.2751 0.1624 0.02707 
 
KMVs 
24 0.2121 0.08714 0.01591  
30 48 0.4242 0.1743 0.03182 
72 0.6363 0.2614 0.04773 
 
LKMVs 
24 0.3529 0.1061 0.02263  
22 48 0.7058 0.2123 0.04526 
72 1.059 0.3184 0.06788 
 
MMVs 
24 0.2534 0.08692 0.01944  
20 48 0.5067 0.1738 0.03887 




24 0.4118 0.1029 0.02750  
14 48 0.8236 0.2058 0.05501 
72 1.235 0.3087 0.08251 
ANOVA: single factor: F= 72.75, DF (14, 351), (P <0.0001). 
 
 
Figure 11. shows the proliferation effect of EMVs  
Discussion and Conclusion  
 In addition to the role in cell communication, EMVs have shown a regenerative 
role in damaged tissues. For instant, K. R. Vrijsen et al. has reported the ability of EMVs 
to improve endothelial cell migration and increase capillary formation in cardiac tissue 
(Vrijsen et al., 2010). Camussi et al. has established that EMVs enhance the regeneration 
process in liver tissue in rat models after 70 % hepatectomy (Camussi et al., 2009). In 
kidneys, S. Bruno et al. has found that EMVs encourage tissue regeneration after acute 






















Clinically, keratinocytes play an essential role in wound epithelization process, and 
without them wounds cannot be healed. Moreover, in chronic non-healing wounds, it has 
been found that compromised keratinocytes at wound edges are responsible for impaired 
wound epithelization and closure (Stojadinovic et al. 2005). 
The role of EMVs in conveying messages and transferring genes horizontally 
between cells has been revealed by Ratajczak et al. and Waldenström et al., in addition to 
their ability to induce the re-programing of recipient cells (Waldenström et al., 2012, 
Ratajczak et al., 2006).  
In this study, we demonstrated that EMVs and growth factors loaded EMVs derived 
from keratinocytes and macrophages promoted cell migration, proliferation accelerated 
wound closure in epidermal keratinocytes in vitro cell model. All these findings about the 
role of EMVs in tissue repair, including our observation, support the hypothesis of potential 
regenerative and therapeutic effects of EMVs and loaded EMVs in wound healing. Further 
investigations are needed to study the potential therapeutic use of EMVs in wound healing.  
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